Santersus AG Receives Second US FDA Breakthrough Device Designation for NucleoCapture in Systemic Lupus Erythematosus
Zurich, Switzerland, 26th Aug 2025 — Santersus AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its...